HOME>Who We Are
Innovation today, healthier tomorrows

Where did Sunovion come from?

What sets us apart? And where are we headed?

If you're interested in answers to these and other questions about Sunovion, you're in the right place.

On November 8, 2013, the U.S. Food and Drug Administration (FDA) approved Aptiom® (eslicarbazepine acetate) tablets, an antiepileptic drug (AED), for use as adjunctive treatment of partial-onset seizures.

Getting started: How we became Sunovion

In October 2009, Sepracor Inc., a U.S. pharmaceutical company with a focus in CNS and Respiratory therapies, was acquired by Sumitomo Dainippon Pharma Co., Ltd., a top ten, stock exchange-listed pharmaceutical company based in Osaka, Japan.

The move strengthened Sumitomo Dainippon Pharma's North American based drug development pipeline and commercial capabilities. And brought together extensive expertise in two main treatment categories—disorders of the central nervous system (CNS) and respiratory diseases.

In April 2010, Sumitomo Dainippon Pharma's original U.S. subsidiary, Dainippon Sumitomo Pharma America, Inc. was merged into Sepracor. Sunovion is the new company born of this union.

What sets Sunovion apart

Sunovion isn't a household name. But we're confident that it will be. We believe our approach sets us apart. An approach characterized by two things.

First, we look beyond science for science's sake. We look at our patients' needs, and the needs of the healthcare professionals who care for them and find practical ways of developing better treatments.

Second, our focus on our patients' needs has led us to specialize in two distinct and broad-based areas of treatment. These days, more people in the United States from children to seniors are living with respiratory diseases. We are committed to improving their daily lives and helping to minimize the impact of their condition on their everyday activities.

We are equally committed to people suffering from disorders of the central nervous system. People with these conditions need new, advanced therapies to treat them effectively. And we're working to discover, develop and deliver the treatments they need. Sunovion's targeted discovery and development program has already resulted in several treatments such as Lunesta® (eszopiclone), a medicine that helps people sleep better.

Other development programs under way at Sunovion are focused on treating CNS conditions like anxiety, depression, and epilepsy, and schizophrenia. Latuda® (lurasidone HCl) tablets was approved by the U.S. Food and Drug Administration (FDA) on October 28, 2010 for the treatment of patients with schizophrenia. LATUDA is available by prescription in pharmacies across the United States.

On June 28, 2013, LATUDA received approval by the U.S. FDA for the treatment of adult patients with depressive episodes associated with bipolar I disorder (bipolar depression), both as monotherapy and as an adjunctive therapy with lithium or valproate.

On November 8, 2013, the U.S. Food and Drug Administration (FDA) approved Aptiom® (eslicarbazepine acetate) tablets, an antiepileptic drug (AED), for use as adjunctive treatment of partial-onset seizures.

  • A new name for a new company, Sunovion brings together two timeless forces: the sun's life-sustaining power and the human power of innovation. Together they represent the life-affirming energy that drives our vision and inspires our people, who strive to realize that vision every day.
  • Our company symbol, the green prism, created by Sumitomo Dainippon Pharma, has long been a source of corporate pride among our colleagues in Japan. From its inception, this symbol has embodied the energy of the sun, the joy of good health, and the hope of the future.